Table 1.
Baseline variables used for propensity score in unweighted and weighted populations.
| Unweighted population | Weighted population | |||||
|---|---|---|---|---|---|---|
| Open (n=580) | Minimally Invasive (n=416) | Unweighted STD | Open (n=580) | Minimally Invasive (n=416) | Weighted STD | |
| Age (years) | 68.6 (±9.2) | 68.9 (±9.0) | 0.04 | 68.7 (9.3) | 69.2 (8.9) | 0.06 |
| Male gender | 422 (72.8%) | 293 (70.4%) | −0.05 | 72.1% | 73.1% | 0.02 |
| Geographic Area | ||||||
| Europe | 319 (55.0%) | 219 (52.6%) | −0.05 | 56.7% | 58.5% | 0.04 |
| North America | 261 (45.0%) | 197 (47.4%) | 0.05 | 43.3% | 41.5% | −0.04 |
| Centers’ volume | ||||||
| High | 275 (47.4%) | 208 (50.0%) | 0.05 | 45.6% | 47.1% | 0.03 |
| Medium | 250 (43.1%) | 167 (40.1%) | −0.06 | 45.0% | 42.5% | −0.05 |
| Low | 55 (9.5%) | 41 (9.9%) | 0.01 | 9.4% | 10.4% | 0.03 |
| Body mass index | ||||||
| <24.9 kg/m 2 | 113 (19.5%) | 80 (19.2%) | 0.00 | 19.5% | 20.1% | 0.01 |
| 25–29.9 kg/m 2 | 204 (35.2%) | 158 (38.0%) | 0.06 | 34.8% | 36.8% | 0.01 |
| ≥ 30 kg/m2 | 263 (45.3%) | 178 (42.8%) | −0.05 | 45.7% | 43.1% | −0.05 |
| Hypertension | 462 (79.7%) | 314 (75.5%) | −0.01 | 78.1% | 77.9% | 0.00 |
| Diabetes | 345 (59.5%) | 219 (52.6%) | −0.14 | 57.9% | 57.7% | 0.00 |
| Ischemic heart disease | 129 (22.2%) | 66 (15.9%) | −0.16 | 19.7% | 19.4% | −0.01 |
| Congestive cardiac failure | 27 (4.7%) | 24 (5.8%) | 0.05 | 5.1% | 4.7% | −0.02 |
| Respiratory disease | 80 (13.8%) | 75 (18.0%) | 0.12 | 15.1% | 16.9% | 0.05 |
| Dyslipidemia | 308 (53.1%) | 225 (54.1%) | 0.02 | 52.8% | 51.6% | −0.02 |
| Previous surgery | 99 (17.1%) | 74 (17.8%) | 0.02 | 17.9% | 19.6% | 0.04 |
| Cirrhosis | 181 (31.2%) | 178 (42.8%) | 0.24 | 34.4% | 34.5% | 0.00 |
| MELD score | 8 (6.4–9) | 8 (6–9.4) | 0.12 | 8 (6.4–9.1) | 7 (6–9) | −0.01 |
| Previous HCC treatment | ||||||
| Locoregional | 73 (12.6%) | 42 (10.1%) | −0.08 | 86.7% | 85.3% | 0.05 |
| Resection | 14 (2.4%) | 9 (2.16%) | −0.02 | 11.2% | 12.7% | −0.01 |
| Year of surgery | ||||||
| 2001–2015 | 415 (71.6%) | 153 (36.8%) | −0.74 | 57.3% | 55.9% | −0.03 |
| 2015–2021 | 165 (28.5%) | 263 (63.2%) | 0.74 | 42.7% | 44.1% | 0.03 |
| Number of lesions | 1 (1–1) | 1 (1–1) | −0.12 | 1 (1–1) | 1 (1–1) | −0.03 |
| Size of lesions (mm) | 55 (36–85) | 40 (27–56) | −0.50 | 50 (32–76) | 48 (32–75) | 0.04 |
| Position of lesions | ||||||
| Anterolateral | 218 (37.6%) | 235 (56.5%) | 0.39 | 44.9% | 46.7% | 0.04 |
| Left lobe | 55 (9.5%) | 30 (7.2%) | −0.08 | 8.6% | 9.0% | 0.01 |
| Posterosuperior | 163 (28.1%) | 111 (26.7%) | −0.03 | 27.6% | 25.1% | −0.06 |
| Right lobe | 144 (24.8%) | 40 (9.6%) | −0.41 | 18.9% | 19.2% | 0.01 |
| Type of hepatectomy | ||||||
| Minor | 353 (60.9%) | 334 (80.3%) | 0.44 | 68.5% | 68.1% | −0.01 |
| Major | 227 (39.1%) | 82 (19.7%) | −0.44 | 31.5% | 31.9% | 0.01 |
STD, Standardized differences. MELD, Model for End Stage Liver Disease. HCC, hepatocellular carcinoma